BIOFRONTERA INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$17M
↑+36.2% +$5Mvs FY2024 (Q4)
Gross Profit
$17M
↑+36.2% +$5Mvs FY2024 (Q4)
Operating Income
$7M
↑+109.5% +$4Mvs FY2024 (Q4)
Net Income
$7M
↑+109.5% +$4Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $17M | $13M |
| COGS | $0 | $0 |
| Gross Profit | $17M | $13M |
| R&D | $787K | $783K |
| SG&A | $9M | $8M |
| D&A | $36K | $38K |
| Other OpEx | $358K | $4K |
| Operating Income | $7M | $4M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $7M | $4M |
| Tax | $0 | $0 |
| Net Income | $7M | $4M |
QuarterCharts · SEC EDGAR data · BFRI · Comparing FY2025 (Q4) vs FY2024 (Q4)